Literature DB >> 26705388

Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque.

Abed Janoudi1, Fadi E Shamoun2, Jagadeesh K Kalavakunta3, George S Abela4.   

Abstract

Evolution of plaque that is prone to rupture is characterized by inflammation and physical changes. Accumulation of low-density lipoprotein in the sub-intima provides esterified cholesterol (ESC) to macrophages and smooth muscle cells that convert it into free cholesterol (FRC) by cholesteryl ester hydrolases (CEHs). Membrane-bound cholesterol carriers transport FRC to high-density lipoprotein (HDL). Impaired HDL transport function and altered composition can lead to extracellular accumulation of FRC, whereas impaired membrane carrier activity can lead to intracellular FRC accumulation. Saturation of FRC can result in cholesterol crystallization with cell death and intimal injury. Disequilibrium between ESC and FRC can impact foam cell and cholesterol crystal (CC) formation. Cholesterol crystals initiate inflammation via NLRP3 inflammasome leading to interleukin-1β (IL-1β) production inducing C-reactive protein. Eventually, crystals growing from within the plaque and associated inflammation destabilize the plaque. Thus, inhibition of inflammation by antagonists to IL-1β or agents that dissolve or prevent CC formation may stabilize vulnerable plaques. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atherosclerosis; Cholesterol crystals; IL-1β; Vascular inflammation; Vulnerable patient; Vulnerable plaque

Mesh:

Substances:

Year:  2015        PMID: 26705388     DOI: 10.1093/eurheartj/ehv653

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  54 in total

1.  Complement Protein C1q Enhances Macrophage Foam Cell Survival and Efferocytosis.

Authors:  Marc C Pulanco; Jason Cosman; Minh-Minh Ho; Jessica Huynh; Karina Fing; Jacqueline Turcu; Deborah A Fraser
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

Review 2.  Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment.

Authors:  Filippo Crea; Peter Libby
Journal:  Circulation       Date:  2017-09-19       Impact factor: 29.690

Review 3.  The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.

Authors:  Angela Pirillo; Fabrizia Bonacina; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Curr Atheroscler Rep       Date:  2018-02-14       Impact factor: 5.113

4.  Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor.

Authors:  Caroline S Gravastrand; Bjørg Steinkjer; Bente Halvorsen; Anne Landsem; Mona Skjelland; Eva Astrid Jacobsen; Trent M Woodruff; John D Lambris; Tom E Mollnes; Ole-Lars Brekke; Terje Espevik; Anne Mari A Rokstad
Journal:  J Immunol       Date:  2019-07-03       Impact factor: 5.422

5.  HDL and ASCVD.

Authors:  Hongtu Cui; Qian Du
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Macrophage molecular signaling and inflammatory responses during ingestion of atherogenic lipoproteins are modulated by complement protein C1q.

Authors:  Minh-Minh Ho; Ayla Manughian-Peter; Weston R Spivia; Adam Taylor; Deborah A Fraser
Journal:  Atherosclerosis       Date:  2016-08-22       Impact factor: 5.162

Review 7.  Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.

Authors:  Claudio Borghi; Alberto Palazzuoli; Matteo Landolfo; Eugenio Cosentino
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

Review 8.  Macrophages in Vascular Inflammation: Origins and Functions.

Authors:  Julius L Decano; Peter C Mattson; Masanori Aikawa
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

Review 9.  Plaque Rupture and Thrombosis: the Value of the Atherosclerotic Rabbit Model in Defining the Mechanism.

Authors:  Oliver G Abela; Chowdhury H Ahsan; Fadi Alreefi; Negar Salehi; Imran Baig; Abed Janoudi; George S Abela
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

10.  Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Authors:  Alla Mitrofanova; Judith Molina; Javier Varona Santos; Johanna Guzman; Ximena A Morales; G Michelle Ducasa; Jonathan Bryn; Alexis Sloan; Ion Volosenco; Jin-Ju Kim; Mengyuan Ge; Shamroop K Mallela; Matthias Kretzler; Sean Eddy; Sebastian Martini; Patricia Wahl; Santiago Pastori; Armando J Mendez; George W Burke; Sandra Merscher; Alessia Fornoni
Journal:  Kidney Int       Date:  2018-10-06       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.